WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

EMA

The European Medicines Agency (EMA) is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. It began operating in 1995.

www.ema.europa.eu

EMA RSS Channel

Filters
List of articles in category EMA
Title Published Date
European Medicines Agency and ENCePP launch electronic Register of Studies 25 November 2010
European Medicines Agency and U.S. Food and Drug Administration extend confidentiality arrangements 20 September 2010
European Medicines Agency holds international workshop on clinical trials 15 September 2010
European Medicines Agency starts review of Pandemrix 31 August 2010
EMA and US FDA seek potential candidate companies for joint GMP inspection programme 12 August 2010
European Medicines Agency starts review of rosiglitazone-containing medicines 15 July 2010
European Medicines Agency implements internal reorganisation 12 October 2009
The bacterial challenge - time to react 18 September 2009
European Medicines Agency review of pandemic vaccines underway 25 July 2009
European public health agencies evaluate antibiotic resistance of Staphylococcus aureus 17 June 2009
European Medicines Agency recommendations on extension of shelf life for Tamiflu 09 May 2009
EMEA-coordinated PROTECT project has been accepted for funding 01 May 2009
EMEA, EC and Health Canada agree implementation plan for confidentiality arrangement 14 April 2009
EMEA recommends suspension of the marketing authorisation of Raptiva (efalizumab) 20 February 2009
European Medicines Agency welcomes continuation of D:A:D study 04 February 2009
EMEA recommends the suspension of the marketing authorisation of Ionsys (fentanyl hydrochloride) 21 November 2008
EMEA recommends suspension of the marketing authorisation of Acomplia 24 October 2008
European Medicines Agency recommends update of product information of Tysabri 26 September 2008
European Medicines Agency recommends restricting the use of oral moxifloxacin-containing medicines 28 July 2008
EMEA recommendation on use of angiotensin II receptor antagonists during pregnancy 25 April 2008
  • Start
  • Prev
  • 1
  • 2
  • 3
  • Next
  • End

Business & Industry

  • Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial
  • Pfizer and BioNTech publish results of study showing COVID-19 vaccine elicits antibodies that neutralize pseudovirus bearing the SARS-CoV-2 U.K. strain spike protein
  • Roche confirms US government agreement to purchase additional doses of Regeneron's casirivimab and imdevimab
  • Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
  • Bayer transforms pharma business through breakthrough innovation in healthcare

Research & Development

  • COVAX announces new agreement, plans for first deliveries
  • Obesity, impaired metabolic health and COVID-19
  • COVID-19 has multiple faces
  • Metformin use reduces risk of death for patients with COVID-19 and diabetes
  • New England Journal of Medicine publishes COVID-19 treatment trial results
  • Scientists identify 'immune cop' that detects SARS-CoV-2
  • New findings help explain how COVID-19 overpowers the immune system

Conferences & Events

  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production
  • Wearable Injectors and Connected Devices Conference 2020

Regulatory Affairs

  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  • FDA takes key action in fight against COVID-19 by issuing Emergency Use Authorization for first COVID-19 vaccine
  • EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2
  1. You are here:  
  2. Home
  3. EMA
  4. Launch of PRIME - Paving the way for promising medicines for patients

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.